Abstracts will be available on the meeting website today,
Presentation Details: Session Date & Time:
Poster No. 308: Safety and Clinical Activity of Multiple Doses of Barzolvolimab, an anti-KIT Antibody, in Patients with Chronic Spontaneous Urticaria
Presenting Author:
Data included in the abstract are through
Data through 24 weeks for Cohorts 1-3 (0.5, 1.5 and 3.0 mg/kg doses)
Data through 20 weeks for Cohort 4 (4.5 mg/kg dose); 6 of 9 patients available at this timepoint as of the data cut-off date
Webcast and Conference Call
The Company will host a webcast presentation of the data on
About
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.
Contact:
Tel: (508) 864-8337
Email: scavanaugh@celldex.com
(C) 2023 Electronic News Publishing, source